Cell-based Therapy for the Treatment of Kidney Disease
试验速览
- 阶段
- 早期 1 期
- 状态
- 尚未招募
- 入组人数
- 10
- 主要终点
- Safety of progenitor cell delivery
研究概览
简要总结
Endothelial progenitor cells derived from and delivered to the renal vasculature may be stimulated to initiate differentiation programs during episodes of injury. It is hypothesized that endothelial progenitor cells from the kidney can transition to a phenotype that promotes endothelial repair.
详细描述
This is an interventional study involving patients that have a diagnosis of chronic kidney disease. Patients will have at least stage 3 chronic kidney disease stage or greater. Kidney-derived endothelial progenitor cells will have been obtained using associated protocols that are currently approved by the Partners Human Research Committee.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 85 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Enrolled patients will have endothelial progenitor cells previously acquired.
排除标准
- •Patients without previously acquired endothelial progenitor cells will be excluded.
结局指标
主要结局
Safety of progenitor cell delivery
时间窗: 180 days
Serum creatinine will be measured after cell delivery
次要结局
未报告次要终点
研究者
Andrew Michael Siedlecki
Assistant Professor of Medicine
Brigham and Women's Hospital